Chiron and Cubist Pharmaceuticals Announce the Filing for EU Regulatory Approval to Market Cubicin -Daptomycin for Injection-.
Business Wire › December 02, 2004
Linked as:
Extract
Chiron and Cubist Pharmaceuticals Announce the Filing for EU Regulatory Approval to Market Cubicin -Daptomycin for Injection-.
EMERYVILLE, Calif. & LEXINGTON, Mass. -- Filing Moves CUBICIN Closer to EU Commercialization
Chiron Corporation (Nasdaq:CHIR) and Cubist Pharmaceuticals, Inc. (Nasdaq:CBST) today announced that Chiron has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) under the European Union's Centralized Procedure for approval to market CUBICIN(R) (daptomycin for injection). The indica...See the full content of this document
Sponsored links
